Skip to main content

NYSEAMERICAN:IBIO - iBio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 55.28 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.61
▲ +0.23 (16.67%)
1 month | 3 months | 12 months
Get New iBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IBIO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$2.50
▲ +55.28% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for iBio in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 55.28% upside from the last price of $1.61.

Buy

The current consensus among 2 contributing investment analysts is to buy stock in iBio.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/21/2021Cantor FitzgeraldInitiated CoverageOverweight$3.00
i
Rating by K. Kluska at Cantor Fitzgerald
11/18/2020Alliance Global PartnersLower Price TargetBuy$3.10 ➝ $2.00
i
11/18/2020Alliance Global PartnersReiterated RatingBuy$3.10 ➝ $2.00
i
Rating by Ben Haynor at Alliance Global Partners
6/26/2020Alliance Global PartnersInitiated CoverageBuy$2.55
i
(Data available from 5/9/2016 forward)
iBio logo
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $1.61
$1.54
$1.95

50 Day Range

MA: $1.33
$1.05
$2.05

52 Week Range

Now: $1.61
$0.96
$7.45

Volume

110,410,300 shs

Average Volume

13,924,231 shs

Market Capitalization

$347.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of iBio?

The following Wall Street sell-side analysts have issued reports on iBio in the last year: Alliance Global Partners, Cantor Fitzgerald, and Zacks Investment Research.
View the latest analyst ratings for IBIO.

What is the current price target for iBio?

2 Wall Street analysts have set twelve-month price targets for iBio in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 55.3%. Cantor Fitzgerald has the highest price target set, predicting IBIO will reach $3.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.00 for iBio in the next year.
View the latest price targets for IBIO.

What is the current consensus analyst rating for iBio?

iBio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IBIO will outperform the market and that investors should add to their positions of iBio.
View the latest ratings for IBIO.

What other companies compete with iBio?

How do I contact iBio's investor relations team?

iBio's physical mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company's listed phone number is +1-302-3550650 and its investor relations email address is [email protected] The official website for iBio is www.ibioinc.com.